SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/GH Secretagogue / ProkineticResearch peptide

Relamorelin

aka RM-131

Ghrelin receptor agonist studied for diabetic gastroparesis and motility disorders.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Relamorelin is a synthetic ghrelin receptor (GHSR-1a) agonist developed primarily as a prokinetic for diabetic gastroparesis rather than for GH release.

Source
  • Investigational pharmaceutical
Forms
  • Subcutaneous injection

Mechanism of action

Activates ghrelin receptors on gastric smooth muscle and the enteric nervous system, accelerating gastric emptying and improving motility.

Pathways
  • · GHSR-1a
  • · Gastric smooth muscle contractility
  • · Enteric nervous system

How it acts on the body

Although ghrelin agonists raise GH, relamorelin was developed and optimized for the prokinetic side of ghrelin biology. In diabetic gastroparesis trials it accelerated gastric emptying and reduced nausea, vomiting, and bloating versus placebo.

The GH effect is present but secondary, and clinical dosing targets motility rather than hormonal output.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

GHIncreases
Secondary effect of ghrelin receptor activation.
Ghrelin signalingIncreases
Direct GHSR-1a agonism.

Effects on the body

Supports
Gastric emptying in diabetic gastroparesis
Decreases
Nausea, vomiting, and postprandial bloating

Organ system effects

Digestive / Gut

Primary site of action — stomach and enteric nervous system.

Endocrine

Secondary GH-axis stimulation.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Targets a condition with few effective options
  • Subcutaneous, short-course dosing

Potential side effects

Common
  • · Hypoglycemia in diabetics
  • · Headache
Rare
  • · Hyperglycemia from improved absorption
  • · Diarrhea
Serious
  • · QT prolongation has not been a major signal

Drug interactions

Insulin and sulfonylureas
Glycemic adjustment required as gastric emptying changes.
moderate

Pairing context

Often combined with
  • Diabetes regimen optimization
    Faster emptying changes insulin timing requirements.
Avoid combining with
  • Mechanical gastric outlet obstruction
    Prokinetic action is contraindicated.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.